OVID vs. IOBT, CHRS, CRDL, HLVX, TCRX, SAVA, ANIX, COYA, CRBP, and HURA
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include IO Biotech (IOBT), Coherus Oncology (CHRS), Cardiol Therapeutics (CRDL), HilleVax (HLVX), TScan Therapeutics (TCRX), Cassava Sciences (SAVA), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Corbus Pharmaceuticals (CRBP), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.
Ovid Therapeutics vs. Its Competitors
Ovid Therapeutics (NASDAQ:OVID) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.
In the previous week, Ovid Therapeutics and Ovid Therapeutics both had 1 articles in the media. IO Biotech's average media sentiment score of 0.95 beat Ovid Therapeutics' score of 0.32 indicating that IO Biotech is being referred to more favorably in the news media.
Ovid Therapeutics presently has a consensus price target of $3.13, indicating a potential upside of 468.18%. IO Biotech has a consensus price target of $9.33, indicating a potential upside of 355.28%. Given Ovid Therapeutics' higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than IO Biotech.
Ovid Therapeutics has higher revenue and earnings than IO Biotech. Ovid Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
IO Biotech has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. Ovid Therapeutics' return on equity of -34.17% beat IO Biotech's return on equity.
Ovid Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by insiders. Comparatively, 4.8% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Ovid Therapeutics beats IO Biotech on 9 of the 14 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ovid Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OVID) was last updated on 7/18/2025 by MarketBeat.com Staff
Free OVID Stock Alerts